Immunopharmacology: Current Applications and Future Perspectives

Dear Colleagues,

Immunopharmacology focuses on the selective control of immune responses and explores advantageous therapeutic alternatives for both conventional and atypical-immune-system-derived clinical conditions. New classes of medications are being introduced as a result of substantial biotechnological developments and progression in acquired knowledge of the immune system. Recent immunopharmacological advancements have resulted in the expansion of clinically relevant drugs that selectively modulate the immune response in a variety of human pathologies, including but not limited to infectious diseases, cancer, chronic inflammatory diseases, cardiovascular disorders, neurological disorders, metabolic disorders, and skeletal disorders. Researchers and physicians in the domains of immunology, pharmacology, and drug discovery must prioritize increasing the efficacy and safety of currently available agents despite the imminent introduction of several novel compounds. In this context, a great deal of research aims at finding interconnections between pharmacology and immunology (and related fields such as immunotoxicology and immunogenetics). All types of immunomodulatory drugs, ranging from small molecules to vaccines and other biological modifiers, are the focus of this Special Issue, which attempts to present the state-of-the-art notions and future perspectives centered on the function of immunopharmacology in the field of therapeutics.

We cordially encourage all researchers to take part in this Special Issue. We welcome the submission of original research, reviews, or shorter perspectives on any topic relevant to immunopharmacology studies. The theme surrounds novel molecular and cellular functions of the key players in immunopharmacology, including novel approaches, advancements in current clinical scenarios, and newly emerging immunomodulators on various types of human pathologies. We particularly encourage the submission of articles on the functional characterization of novel rational medication combinations involving immunomodulators. Moreover, special emphasis will be placed on the causes and consequences of immunotherapy as a treatment for various diseases. Additionally, relevant ideas include single and combined drug therapies, the identification of novel mechanisms for drug-targeting therapies, and the creation of new logical drug combinations.

Dr. Javier Conde Aranda
Dr. Vishakha Anand Pawar
Dr. Vinay Kumar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• drug discovery
• immunotherapy
• immunopharmacology
• human diseases